Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of retigabine/ezogabine in adolescents and young adults with partial onset seizures or Lennox-Gastaut syndrome
2010-020154-33Phase 3
- Sponsor
- GSK
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of retigabine in Focal Onset Epilepsy and Lennox-Gastaut syndrome (LGS) (2 arms), sponsored by GSK. Primary endpoint: Incidence of adverse events and serious adverse events.
02
Drugs
retigabine
03
Conditions
Focal Onset EpilepsyLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2010-020154-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020154-33.